1 hour ago
1
- Bayer (OTCPK:BAYZF) (OTCPK:BAYRY) and Kumquat Biosciences said that they have entered into an exclusive global license deal to develop and sell Kumquat's KRAS G12D inhibitor, a cancer treatment.
- Under the deal, Kumquat could earn up to $1.3B, which includes initial payments, milestones during clinical
English (US) ·